Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments

1 organizations filed 1 public comment on Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments, at the Food and Drug Administration. The comment window closed 1527d ago.

Commenters (1)

• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%